Cyclosporine in the treatment of psoriasis.
The efficacy of cyclosporine is well documented in multiple clinical trials. Patients with severe psoriasis who require systemic treatment should be considered for this therapeutic agent. The need for both a careful evaluation prior to therapy and strict monitoring of the patient cannot be over emphasized because untreated hypertension, renal dysfunction, and other disorders may lead to serious, nonreversible morbidity. Physicians are encouraged to follow the published guidelines for controlling psoriasis in their patients and lowering the risk of potential drug toxicity.
Gulliver
W P
WP
Department of Medicine, Memorial University of Newfoundland, St. John's, Canada.
D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D004347:Drug Interactions; D005500:Follow-Up Studies; D006801:Humans; D007668:Kidney / Q000187:drug effects; D018579:Patient Selection; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000139:chemically induced; D013997:Time Factors
D003879:Dermatologic Agents; D016572:Cyclosporine; D003404:Creatinine